Anbio Biotechnology Operating Income Over Time
| NNNN Stock | 39.00 2.11 5.13% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Anbio Biotechnology Performance and Anbio Biotechnology Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anbio Biotechnology. If investors know Anbio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anbio Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.028 | Earnings Share 0.06 | Revenue Per Share | Quarterly Revenue Growth (0.22) | Return On Assets |
The market value of Anbio Biotechnology Class is measured differently than its book value, which is the value of Anbio that is recorded on the company's balance sheet. Investors also form their own opinion of Anbio Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Anbio Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anbio Biotechnology's market value can be influenced by many factors that don't directly affect Anbio Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anbio Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anbio Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anbio Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Anbio Biotechnology Class and related stocks such as AngioDynamics, Talkspace, and Clearpoint Neuro Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANGO | (290 K) | (3.9 M) | 6.3 M | 10.5 M | (3.4 M) | 1 M | (11.2 M) | (14.2 M) | (9.4 M) | (167.1 M) | (35.3 M) | (28.5 M) | (51.2 M) | (192.4 M) | (40 M) | (36 M) | (34.2 M) |
| TALK | (29.4 M) | (29.4 M) | (29.4 M) | (29.4 M) | (29.4 M) | (29.4 M) | (29.4 M) | (29.4 M) | (29.4 M) | (29.4 M) | (22 M) | (93.9 M) | (77 M) | (23.2 M) | (4.5 M) | (5.2 M) | (5.4 M) |
| CLPT | (9.5 M) | (5.9 M) | (3.1 M) | (7.5 M) | (5.3 M) | (9 M) | (7.5 M) | (6.3 M) | (5.2 M) | (4.6 M) | (6.2 M) | (13.4 M) | (16.3 M) | (22.4 M) | (19.7 M) | (17.8 M) | (16.9 M) |
| CYH | 105.3 M | 1.1 B | 1.2 B | 917 M | 1.3 B | 1.3 B | (860 M) | (1.9 B) | 208 M | 650 M | 1.1 B | 1.4 B | 821 M | 957 M | 542 M | 623.3 M | 621.5 M |
| CMPS | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (21.2 M) | (51.8 M) | (83.2 M) | (110.4 M) | (136.9 M) | (178.2 M) | (160.4 M) | (152.4 M) |
| AVNS | 207.9 M | 207.9 M | 226.5 M | 222.9 M | 311.5 M | 154.8 M | (69.4 M) | (16 M) | 34.9 M | (5.4 M) | 70.9 M | 86.8 M | 41.9 M | 65 M | 40 M | 36 M | 34.2 M |
| KALV | (1.8 M) | (1.8 M) | (1.8 M) | (5.2 M) | (11.7 M) | (24.2 M) | (22.3 M) | (18.7 M) | (29.8 M) | (40.5 M) | (57.9 M) | (96.6 M) | (110.9 M) | (140.4 M) | (188 M) | (24.2 M) | (25.4 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.7 M) | (149 M) | (186.1 M) | (210.6 M) | (216.1 M) | (218.6 M) | (183.8 M) | (59.9 M) | (53.9 M) | (56.6 M) |
| RIGL | (12.1 M) | (86.4 M) | (99.4 M) | (89.5 M) | (91.2 M) | (51.7 M) | (69.7 M) | (79.6 M) | (72.7 M) | (69.1 M) | (29 M) | (12.5 M) | (55.5 M) | (20.5 M) | 24.2 M | 27.8 M | 29.2 M |
| SNDL | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (12.9 M) | (1.5 M) | (52.4 M) | (185.4 M) | (134.4 M) | (347.8 M) | (163.2 M) | (103.8 M) | (93.4 M) | (98.1 M) |
Anbio Biotechnology Class and related stocks such as AngioDynamics, Talkspace, and Clearpoint Neuro Operating Income description
Operating Income is the amount of profit realized from Anbio Biotechnology Class operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Anbio Biotechnology Class is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Anbio Biotechnology Class | NNNN |
| Classification | Biotech |
| Business Address | Wilhelm Gutbrod Str |
| Exchange | NASDAQ Exchange |
null 39.0
Check out Anbio Biotechnology Performance and Anbio Biotechnology Correlation. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Anbio Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.